BioCentury
ARTICLE | Company News

Lung Therapeutics raises $14.3M series B round

June 7, 2017 12:07 AM UTC

Lung Therapeutics Inc. (Austin, Texas) raised $14.3 million in a series B round led by Bios Partners. Founding investor UT Horizon Fund also participated.

Lung’s lead product LTI-01, a single-chain urokinase plasminogen activator, is in a Phase Ia/Ib trial to treat loculated pleural effusions in patients with pneumonia. CEO Brian Windsor told BioCentury the company hopes to finish the study by YE17...

BCIQ Company Profiles

Lung Therapeutics Inc.